AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24238825 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tranexamic acid
Number of subjects: 100
Study 22678318 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium endoclip
Number of subjects: 61
Study 22678318 — intervention group
Group type: COMPARATOR
Intervention: Knot-tying (polyglactin) suture
Number of subjects: 61
Study 20232751 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous antioxidants
Number of subjects: 0
Study 18814408 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytotherapy (herbal medicine)
Number of subjects: 20
Study 18814408 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 16075255 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia (TIVA) using propofol/remifentanil
Number of subjects: 40
Study 16075255 — intervention group
Group type: COMPARATOR
Intervention: Balanced minimal flow anesthesia using desflurane/remifentanil
Number of subjects: 40
Study 16075255 — intervention group
Group type: EXPERIMENTAL
Intervention: Total anesthesia costs for both groups
Number of subjects: 40
Study 12430113 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Controlled Femoral Analgesia (PCFA) with 0.2% ropivacaine (boluses of 10 mL with a lockout time of 60 minutes)
Number of subjects: 140
Study 12430113 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Femoral Infusion (Inf) with 0.2% ropivacaine (10 mL/h)
Number of subjects: 140
Study 12430113 — intervention group
Group type: EXPERIMENTAL
Intervention: PCFA + Inf with 0.2% ropivacaine (5 mL/h plus boluses of 5 mL with a lockout time of 60 minutes)
Number of subjects: 140
Study 10412269 — intervention group
Group type: EXPERIMENTAL
Intervention: P53 positive tumours
Number of subjects: 115
Study 10412269 — intervention group
Group type: EXPERIMENTAL
Intervention: MDM2 positive tumours
Number of subjects: 115
Study 10412269 — intervention group
Group type: EXPERIMENTAL
Intervention: P53(‐)/MDM2(+) phenotype
Number of subjects: 115
Study 10412269 — intervention group
Group type: EXPERIMENTAL
Intervention: Both P53 and MDM2 positive tumours
Number of subjects: 115
Study 10412269 — intervention group
Group type: EXPERIMENTAL
Intervention: Only P53 positive tumours
Number of subjects: 115
Study 10412269 — intervention group
Group type: EXPERIMENTAL
Intervention: P53 accumulation
Number of subjects: 115
Study 10412269 — intervention group
Group type: EXPERIMENTAL
Intervention: MDM2 immunoreactivity
Number of subjects: 115
Study 7479189 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% acid red in propylene glycol
Number of subjects: 221
Study 7479189 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% povidone-iodine in water
Number of subjects: 221
Study 3067086 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillamine and vitamin E
Number of subjects: 106
Study 3067086 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 29533525 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based antenatal care and education program
Number of subjects: 135
Study 29533525 — intervention group
Group type: COMPARATOR
Intervention: Routine antenatal care
Number of subjects: 135
Study 28498207 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 units of hyaluronidase
Number of subjects: 15
Study 28498207 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 units of hyaluronidase
Number of subjects: 15
Study 28498207 — intervention group
Group type: COMPARATOR
Intervention: No secondary injection
Number of subjects: 15
Study 28498207 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 15
Study 28498207 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of 20 vs 40 units of hyaluronidase
Number of subjects: 15
Study 26775356 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined general/epidural anesthesia
Number of subjects: 85
Study 26775356 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia alone
Number of subjects: 85
Study 23748819 — intervention group
Group type: EXPERIMENTAL
Intervention: megesterol acetate (MA) plus meloxicam (n = 23)
Number of subjects: 62
Study 23748819 — intervention group
Group type: EXPERIMENTAL
Intervention: MA plus meloxicam plus oral eicosapentaenoic acid (EPA)-enriched nutritional supplement (n = 21)
Number of subjects: 62
Study 23748819 — intervention group
Group type: EXPERIMENTAL
Intervention: meloxicam plus oral EPA-enriched nutritional supplement (n = 18)
Number of subjects: 62
Study 20655544 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral treatment with peer-enhanced adventure therapy
Number of subjects: 118
Study 20655544 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behavioral weight control treatment with supervised aerobic exercise
Number of subjects: 118
Study 18209781 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-HTP 100 mg/day
Number of subjects: 8
Study 18209781 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 20728977 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum-acupuncture (Group 1, n = 47)
Number of subjects: 101
Study 20728977 — intervention group
Group type: COMPARATOR
Intervention: Non-specific acupuncture (Group 2, n = 54)
Number of subjects: 101
Study 16236227 — intervention group
Group type: COMPARATOR
Intervention: Resistance training placebo (n=10)
Number of subjects: 42
Study 16236227 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance trained creatine supplemented (n=10)
Number of subjects: 42
Study 16236227 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance trained protein supplemented (n=11)
Number of subjects: 42
Study 16236227 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance trained creatine and protein supplemented (n=11)
Number of subjects: 42
Study 11906645 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF-stimulated peripheral blood stem cell (PBSC) infusion with cyclosporin A (CsA) and 0.4 mg/kg prednisolone
Number of subjects: 44
Study 11906645 — intervention group
Group type: COMPARATOR
Intervention: Control group received azathioprine, 1 mg/kg prednisolone, and CsA
Number of subjects: 44
Study 11906645 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF 450 microg on four consecutive days followed by leucopheresis and immediate transfusion of unmodified PBSC
Number of subjects: 44
Study 10958254 — intervention group
Group type: EXPERIMENTAL
Intervention: venlafaxine
Number of subjects: 102
Study 10958254 — intervention group
Group type: COMPARATOR
Intervention: clomipramine
Number of subjects: 102
Study 7934600 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapitrac method (blind)
Number of subjects: 55
Study 7934600 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapitrac method (fiberoptic bronchoscope)
Number of subjects: 55
Study 7934600 — intervention group
Group type: COMPARATOR
Intervention: Dissection method
Number of subjects: 55
Study 3209716 — intervention group
Group type: EXPERIMENTAL
Intervention: brofaromine (BROF)
Number of subjects: 49
Study 3209716 — intervention group
Group type: EXPERIMENTAL
Intervention: tranylcypromine (TCP)
Number of subjects: 49
Study 3209716 — intervention group
Group type: COMPARATOR
Intervention: unmedicated subjects
Number of subjects: 49
Study 12362118 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (25-95 units per muscle based on Ashworth score)
Number of subjects: 20
Study 31362741 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab 100 mg SC
Number of subjects: 936
Study 31362741 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 936
Study 29982723 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Sweeteners Beverage (HISB) - 2 cans (330 mL each)/d for 12 weeks
Number of subjects: 60
Study 29982723 — intervention group
Group type: COMPARATOR
Intervention: Unsweetened Beverage (UB) - 2 cans (330 mL each)/d for 12 weeks
Number of subjects: 60
Study 29982723 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Sweeteners Beverage (HISB)
Number of subjects: 60
Study 29982723 — intervention group
Group type: COMPARATOR
Intervention: Unsweetened Beverage (UB)
Number of subjects: 60
Study 27821109 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 68
Study 27821109 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 68
Study 23861381 — intervention group
Group type: EXPERIMENTAL
Intervention: Biventricular (BIV) pacing
Number of subjects: 53
Study 23861381 — intervention group
Group type: COMPARATOR
Intervention: Right ventricular (RV) pacing
Number of subjects: 53
Study 22152616 — intervention group
Group type: EXPERIMENTAL
Intervention: PathFile (PF) - NiTi rotary glide path
Number of subjects: 149
Study 22152616 — intervention group
Group type: COMPARATOR
Intervention: Stainless-steel K-file (KF) - manual glide path
Number of subjects: 149
Study 20224007 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum strain WCFS1 administered in the duodenum for 6 hours via feeding catheter
Number of subjects: 0
Study 20224007 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum
Number of subjects: 0
Study 20224007 — intervention group
Group type: EXPERIMENTAL
Intervention: TLR2 agonist Pam(3)‐Cys‐SK4 (PCSK)
Number of subjects: 0
Study 20224007 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum or PCSK
Number of subjects: 0
Study 17507823 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antimicrobials limited to <48 hours postoperatively
Number of subjects: 374
Study 17507823 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopeptides recommended for high-risk patients
Number of subjects: 374
Study 17507823 — intervention group
Group type: COMPARATOR
Intervention: No intervention applied
Number of subjects: 374
Study 16389694 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (glucagon‐like peptide‐1 agonist)
Number of subjects: 0
Study 16389694 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11879382 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg LTG
Number of subjects: 30
Study 11879382 — intervention group
Group type: COMPARATOR
Intervention: VPA 900 mg
Number of subjects: 30
Study 11879382 — intervention group
Group type: COMPARATOR
Intervention: PBO
Number of subjects: 30
Study 11879382 — intervention group
Group type: EXPERIMENTAL
Intervention: LTG
Number of subjects: 30
Study 11879382 — intervention group
Group type: COMPARATOR
Intervention: VPA
Number of subjects: 30
Study 10229128 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) therapy
Number of subjects: 11
Study 10229128 — intervention group
Group type: EXPERIMENTAL
Intervention: IgM antibodies to nerve glycoconjugates
Number of subjects: 11
Study 7887643 — intervention group
Group type: EXPERIMENTAL
Intervention: FP (400 mg/m2 UFT po daily and 50 mg/m2 CDDP i.v. on days 1 and 8 every 4 weeks)
Number of subjects: 48
Study 7887643 — intervention group
Group type: COMPARATOR
Intervention: FEP (400 mg/m2 UFT po daily, 50 mg/m2 etoposide iv and 50 mg/m2 CDDP i.v. on days 1 and 8 every 4 weeks)
Number of subjects: 48
Study 2167953 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP; 120 mg/m2, day 1) plus etoposide (VP16; 100 mg/m2, days 1, 2, and 3)
Number of subjects: 228
Study 2167953 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin (CBDCA; 325 mg/m2, day 1) plus etoposide (VP16; 100 mg/m2, days 1, 2, and 3)
Number of subjects: 228
Study 598412 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin 0.4 mg i.v. daily for 14 days
Number of subjects: 5
Study 598412 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-methyldigoxin 0.4 mg i.v. daily for 14 days
Number of subjects: 5
Study 31801679 — intervention group
Group type: EXPERIMENTAL
Intervention: TWHF 60 mg/d plus valsartan 160 mg/d
Number of subjects: 124
Study 31801679 — intervention group
Group type: COMPARATOR
Intervention: Valsartan 160 mg/d
Number of subjects: 124
Study 30607527 — intervention group
Group type: EXPERIMENTAL
Intervention: EBP training methods
Number of subjects: 200
Study 30607527 — intervention group
Group type: EXPERIMENTAL
Intervention: Organizational climate
Number of subjects: 200
Study 28943100 — intervention group
Group type: EXPERIMENTAL
Intervention: Ubiquinol 300mg/day
Number of subjects: 0
Study 28943100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25858085 — intervention group
Group type: EXPERIMENTAL
Intervention: Gow-Gates (GG) technique
Number of subjects: 136
Study 25858085 — intervention group
Group type: COMPARATOR
Intervention: Standard technique of inferior alveolar nerve block (IANB)
Number of subjects: 136
Study 23530837 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous tissue closure with staples
Number of subjects: 218
Study 23530837 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous tissue closure with intracutaneous sutures
Number of subjects: 218
Study 23530837 — intervention group
Group type: COMPARATOR
Intervention: No subcutaneous tissue closure with staples
Number of subjects: 218
Study 23530837 — intervention group
Group type: COMPARATOR
Intervention: No subcutaneous tissue closure with intracutaneous sutures
Number of subjects: 218
Study 21632811 — intervention group
Group type: EXPERIMENTAL
Intervention: Early metformin (study years 1-4; age 8-12 years)
Number of subjects: 38
Study 21632811 — intervention group
Group type: COMPARATOR
Intervention: Late metformin (year 6; age 13-14 years)
Number of subjects: 38
Study 19492197 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyurethane ChemoSite (AutoSuture)
Number of subjects: 228
Study 19492197 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyurethane Port‐a‐Cath (Pharmacia‐Upjohn)
Number of subjects: 228
Study 19492197 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone Port‐a‐Cath
Number of subjects: 228
Study 19492197 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 228
Study 16950076 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 275
Study 16950076 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 275
Study 12589702 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (n = 44)
Number of subjects: 171
Study 12589702 — intervention group
Group type: COMPARATOR
Intervention: Control (Placebo, n = 38)
Number of subjects: 171
Study 12589702 — intervention group
Group type: COMPARATOR
Intervention: Control (Dietary intervention, n = 42)
Number of subjects: 171
Study 12589702 — intervention group
Group type: COMPARATOR
Intervention: Control (Fish oil supplementation + dietary intervention, n = 47)
Number of subjects: 171
Study 12589702 — intervention group
Group type: COMPARATOR
Intervention: Control (n = 80, without fish oil supplementation)
Number of subjects: 171
Study 12589702 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (n = 91)
Number of subjects: 171
Study 10632907 — intervention group
Group type: COMPARATOR
Intervention: Single injection (Group S)
Number of subjects: 70
Study 10632907 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple fractionated doses (Group M)
Number of subjects: 70
Study 10632907 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study 8857677 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood cardioplegia (BCP)
Number of subjects: 100
Study 8857677 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid cardioplegia (CCP)
Number of subjects: 100
Study 1995175 — intervention group
Group type: EXPERIMENTAL
Intervention: 5F catheters via percutaneous right brachial artery approach
Number of subjects: 60
Study 1995175 — intervention group
Group type: COMPARATOR
Intervention: 5F catheters via femoral route
Number of subjects: 60
Study 1995175 — intervention group
Group type: COMPARATOR
Intervention: 8F catheters via femoral route
Number of subjects: 60
Study 6390207 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric evaluation unit
Number of subjects: 123
Study 6390207 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 123
Study 31255587 — intervention group
Group type: EXPERIMENTAL
Intervention: Glasses
Number of subjects: 119
Study 31255587 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 119
Study 29481640 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise plus TrP‐DN
Number of subjects: 50
Study 29481640 — intervention group
Group type: COMPARATOR
Intervention: Exercise alone
Number of subjects: 50
Study 27669457 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (n=818)
Number of subjects: 1635
Study 24266598 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time guidance WED
Number of subjects: 163
Study 24266598 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance guidance WED
Number of subjects: 163
Study 24266598 — intervention group
Group type: COMPARATOR
Intervention: Standard WED
Number of subjects: 163
Study 24266598 — intervention group
Group type: COMPARATOR
Intervention: Control writing
Number of subjects: 163
Study 22248749 — intervention group
Group type: EXPERIMENTAL
Intervention: Pituitrin (0.017‐0.042 U/min, 1.0‐2.5 U/h)
Number of subjects: 139
Study 22248749 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine (NE)
Number of subjects: 139
Study 20813217 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted influenza vaccine
Number of subjects: 1726
Study 20813217 — intervention group
Group type: COMPARATOR
Intervention: Non-adjuvanted influenza vaccine
Number of subjects: 1726
Study 17410588 — intervention group
Group type: EXPERIMENTAL
Intervention: First-trimester sonographic examinations
Number of subjects: 52
Study 17410588 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 52
Study 15846270 — intervention group
Group type: EXPERIMENTAL
Intervention: TEE-guided strategy (n = 544)
Number of subjects: 1222
Study 15846270 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (n = 530)
Number of subjects: 1222
Study 15846270 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with CHF
Number of subjects: 1222
Study 15846270 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall group data
Number of subjects: 1222
Study 12224004 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal daunorubicin (DaunoXome) combined with high-dose arabinosyl cytosine (HDAC)
Number of subjects: 42
Study 9626770 — intervention group
Group type: EXPERIMENTAL
Intervention: Chimeric anti-CD4 antibody treatment
Number of subjects: 30
Study 9626770 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 30
Study 8070481 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroximone 5 micrograms.kg‐1.min‐1
Number of subjects: 18
Study 8070481 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroximone 10 micrograms.kg‐1.min‐1
Number of subjects: 18
Study 8070481 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 2963533 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron (Fe) supplementation
Number of subjects: 0
Study 2963533 — intervention group
Group type: EXPERIMENTAL
Intervention: Folate supplementation
Number of subjects: 0
Study 31160317 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR decrease ≥40%
Number of subjects: 8766
Study 31160317 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR increase ≥40%
Number of subjects: 8766
Study 31160317 — intervention group
Group type: EXPERIMENTAL
Intervention: UACR decrease ≥40%
Number of subjects: 8766
Study 31160317 — intervention group
Group type: EXPERIMENTAL
Intervention: UACR increase ≥40%
Number of subjects: 8766
Study 31160317 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR decrease ≥40% and UACR increase ≥40%
Number of subjects: 8766
Study 27873545 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic lozenges containing Lactobacillus reuteri
Number of subjects: 47
Study 27873545 — intervention group
Group type: COMPARATOR
Intervention: Placebo lozenges
Number of subjects: 47
Study 25678453 — intervention group
Group type: EXPERIMENTAL
Intervention: EG‐1962 (nimodipine microparticles)
Number of subjects: 0
Study 25678453 — intervention group
Group type: COMPARATOR
Intervention: Oral nimodipine (active control)
Number of subjects: 0
Study 25678453 — intervention group
Group type: EXPERIMENTAL
Intervention: EG‐1962
Number of subjects: 0
Study 24419239 — intervention group
Group type: EXPERIMENTAL
Intervention: Motesanib plus carboplatin/paclitaxel (C/P)
Number of subjects: 227
Study 24419239 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus carboplatin/paclitaxel (C/P)
Number of subjects: 227
Study 21752575 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day-CPM
Number of subjects: 84
Study 21752575 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day-CPM
Number of subjects: 84
Study 21752575 — intervention group
Group type: COMPARATOR
Intervention: no-CPM
Number of subjects: 84
Study 19011721 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5D
Number of subjects: 114
Study 19011721 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-6D
Number of subjects: 114
Study 19011721 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 114
Study 17703786 — intervention group
Group type: EXPERIMENTAL
Intervention: High evaluation threat
Number of subjects: 72
Study 17703786 — intervention group
Group type: COMPARATOR
Intervention: Low evaluation threat
Number of subjects: 72
Study 14988902 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated stents
Number of subjects: 1
Study 11930611 — intervention group
Group type: EXPERIMENTAL
Intervention: Touch intervention (conducted 2-3 times/day for 15-20 minutes for at least 3 months)
Number of subjects: 310
Study 11930611 — intervention group
Group type: EXPERIMENTAL
Intervention: Touch intervention (conducted within one month after birth)
Number of subjects: 310
Study 11930611 — intervention group
Group type: COMPARATOR
Intervention: Control group (no touch intervention)
Number of subjects: 310
Study 11930611 — intervention group
Group type: COMPARATOR
Intervention: Touch intervention and Control group
Number of subjects: 310
Study 9039623 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic contrast-enhanced MR imaging with gadolinium‐diethylenetriamine penta‐acetic acid (Gd‐DTPA) at a dosage of 0.1 mmol/kg body weight.
Number of subjects: 75
Study 9039623 — intervention group
Group type: COMPARATOR
Intervention: Dynamic contrast-enhanced MR imaging with Gd-DTPA.
Number of subjects: 75
Study 9039623 — intervention group
Group type: EXPERIMENTAL
Intervention: MR imaging follow-up during therapy in patients with B-CLL.
Number of subjects: 75
Study 9039623 — intervention group
Group type: EXPERIMENTAL
Intervention: Out-of-phase imaging with Gd-DTPA.
Number of subjects: 75